MedTrace Logo

Nebulizer Delivery of Intranasal Scopolamine

NCT04999449 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-08-28

No results posted yet for this study

Summary

To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer.

Conditions

Interventions

DRUG

Scopolamine

Intranasal scopolamine at 0.2 mg or 0.4 mg

DRUG

Placebo

Intranasal saline placebo

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Principal Investigators

  • Jay C Buckey, Ph.D · Dartmouth-Hitchcock Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-24
Primary Completion
2025-05-07
Completion
2025-05-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999449 on ClinicalTrials.gov